Latest From Neurologix Inc.
Once expected to be absorbed by Sanofi, US biotech Warp Drive Bio now will become part of California’s Revolution Medicines in a stock transaction. Sosei elects against its option to acquire MiNA Therapeutics; MeiraGTX follows its June IPO with takeout of Vector Neurosciences. Other recent mergers and acquisitions...
A profound redefinition of the role of many cell types and biomaterials in regenerative medicine is under way as researchers have moved away from the notion that cells introduced into the body will integrate and become functioning tissue.
After a decade of doubts, fears, and scares, advances in gene therapy have brought one drug close to approval, and a few venture-backed start-ups are gaining momentum. Is it enough to persuade more VCs to jump in?
Neurologix Inc. filed for voluntary Chapter 7 bankruptcy protection in US Bankruptcy Court for the District of Delaware on 16 March to liquidate assets after it spent the past year looking for financing or a partner to advance its Parkinson's disease gene therapy into Phase III clinical trials.
- Gene Therapy, Cell Therapy
- Large Molecule
- Drug Delivery
- Therapeutic Areas
- Neurology, Nervous System
- North America
- Parent & Subsidiaries
- Neurologix Inc.
- Senior Management
Marc L Panoff, CFO, Treasurer & Secretary
Christine V Sapan, PhD, EVP & Chief Dev. Officer
Andrew I Koven, Pres. & Chief Admin. Officer
- Contact Info
Phone: (201) 592-6451
One Bridge Plaza
Fort Lee, NJ 07024
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.